|Study Description:||The goal of the Phase I part of this clinical research study is to find the |
highest tolerable dose of the drug Yervoy (ipilimumab) that can be given with
the drugs Temodar (temozolomide), Intron-A (interferon alfa-2b), Proleukin
(aldesleukin, IL-2), and Platinol (cisplatin) to patients with metastatic
melanoma. The safety of this combination will also be studied in Phase I. The
goal of Phase II is to learn if this combination can help to control metastatic
Ipilimumab, interferon alfa-2b, and aldesleukin are designed to block the
activity of cells that decrease the immune system's ability to fight cancer.
Temozolomide is designed to stop cancer cells from making new DNA (the genetic
material of cells). This may stop the cancer cells from dividing into new
Cisplatin is designed to poison the cancer cells, which may cause them to die.